Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest BRAF Stories

2013-02-04 08:26:36

BURLINGTON, Mass., Feb. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the United States and Europe due to the expected approval of several new therapies. In addition to Exelixis's Cometriq (cabozantinib) for advanced medullary thyroid carcinomas (MTC)--which was approved in the U.S. late last...

2013-01-29 20:21:17

BOULDER, Colo., Jan. 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2013 on Monday, February 4, 2013, and will hold a conference call on Tuesday, February 5, 2013 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call. Conference Call Information Date: Tuesday,...

2013-01-03 04:20:28

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) Researchers will use Trovagene's proprietary transrenal DNA (TrDNA) detection technology...

2012-11-29 14:19:28

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute. Metastatic colorectal cancer patients whose tumors harbor mutations in KRAS (and to a lesser extent, in BRAF) are unlikely to respond to costly anti-EGFR therapies. Screening of patients who are...

2012-11-08 12:27:27

BOULDER, Colo., Nov. 8, 2012 /PRNewswire/ -- At its R&D Investor event earlier today, Novartis provided an update on the clinical development strategy for MEK162 (ARRY-162). Novartis intends to initiate pivotal trials in patients with NRAS mutant melanoma during 2013, with the goal of regulatory submissions on or after 2016. In addition, Novartis announced plans to pursue clinical development in combination with a Raf inhibitor, in BRAF mutant melanoma, with regulatory submissions...

2012-10-25 04:01:03

GlaxoSmithKline is experimenting with a new combination of cancer medications; Petra Rietschel, MD encourages such exploration. White Plains, New York (PRWEB) October 24, 2012 Bloomberg Businessweek reports that GlaxoSmithKline Plc has combined two medications designed to treat melanoma in an effort to slow the growth of the cancer. According to the article, a study has found that this combination has succeeded in limiting the progression of the disease more successfully than a single-drug...

2012-10-01 12:24:55

Promising new data from trials aimed at delaying resistance to BRAF inhibitors Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. The phase I and II trials focus on combining drugs to slow the development of resistance to drugs that inhibit BRAF, a gene that is mutated in about half of melanomas. Earlier trials with drugs that target BRAF generated excitement for their...

2012-05-31 10:25:03

SEATTLE, May 31, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib (Zelboraf®).  PX-866 is Oncothyreon's investigational small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.  Vemurafenib is a kinase inhibitor indicated for the treatment of unresectable or metastatic...

2012-05-31 02:25:17

TUCSON, Ariz., May 31, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein. This...

2012-05-21 05:26:29

(Ivanhoe Newswire) — Some say the number of cases is growing at an epidemic rate! In fact, melanoma is the fastest growing cancer in the U.S. Now, a new study shows the drug, dabrafenib, has been shown to have the most activity of any systematic treatment to date against secondary melanoma tumours in the brain. A phase 1 trial shows the new drug causes substantial shrinking of metastatic tumours in patients. Dabrafenib blocks the activity of the cancer-causing mutated form of the...